Drug intelligence / Profile preview

DLO6001

Development stage: Preclinical
Lead developer: Summit Therapeutics
Modality: Small Molecules

Overview

DLO6001 is a drug developed by DanioLabs using proprietary zebrafish technology. It is being investigated for the treatment of symptoms associated with Parkinson's disease, specifically targeting sialorrhoea (excessive salivation) and hyperhidrosis (excessive sweating). The precise mechanism of action has not been disclosed in public sources. The drug represents a novel approach to symptomatic management in Parkinson's disease, focusing on non-motor symptoms that significantly impact patient quality of life[1][3].

Beyond the preview

Go deeper on DLO6001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DLO6001.

Explore the full profile